Intrapulmonary rFVIIa for life threatening pulmonary hemorrhage in a case of relapsing acute lymphoblastic leukemia and platelet refractoriness

References

• Smith LJ, Katzenstein AL. Pathogenesis of massive pulmonary hemorrhage in acute leukemia. Arch Intern Med 1982;142:2149–2152
   PubMedGoogle Scholar
• Afessa B, Tefferi A, Litzow MR, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002;166:1364–1368
   PubMed Web of Science ®Google Scholar
• Vassallo RR. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients. Immunohematology 2009;25:119–124
   PubMedGoogle Scholar
• Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007;172–178
   PubMedGoogle Scholar
• Heuer L, Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinolysis 2005;16:287–290
   PubMed Web of Science ®Google Scholar
• Kalmadi S, Tiu R, Lowe C, Jin T, Kalayacio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 2006;107:136–140
   PubMed Web of Science ®Google Scholar
• Zeigler ZR, Shadduck RK, Rosenfeld CS, Winkelstein A, Przepiorka D, Kiss JE, Duquesnoy RJ, Marrari M. Intravenous gamma globulin decreases platelet-associated IgG and improves transfusion responses in platelet refractory states. Am J Hematol 1991;38:15–23
   PubMed Web of Science ®Google Scholar
• Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002;30:975–978
   PubMed Web of Science ®Google Scholar
• Lindley CM, Sawayer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant Factor VIIa. Clin Pharmacol Therapeut 1994;55:638–648
   PubMed Web of Science ®Google Scholar
• Poon MC. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa? Curr Hematol Rep 2003;2:139–147
   PubMedGoogle Scholar
• Pastores SM, Papadopoulos E, Voigt P, Halpern NA. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest 2003;124:2400–2403
   PubMed Web of Science ®Google Scholar
• De Fabritis P. Recombinant factor VIIa for the management of severe hemorrhage in patients with hematologic malignancies. Haematologica 2004;89:243–245
   PubMed Web of Science ®Google Scholar
• Henke D. Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med 2004;140:493–494
   PubMed Web of Science ®Google Scholar
• Heslet L, Nielsen JD, Levi M, Sengelov H, Johansson PI. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Critical Care 2006;10:1--6
   Web of Science ®Google Scholar
• Grochova M, Kalnasova B, Firment J, Olejarova I, Roland R, Lazurova I. Pulmonary administration of activated recombinant factor VII. Bratisl Lek Listy 2011;112:29–33
   PubMed Web of Science ®Google Scholar
• Agrawal A, Gustavo F. Intrapulmonary use of activated factor VII in uncontrolled pulmonary hemorrhage: A case report and review of literature. Chest 2012;142:336A
   Google Scholar
• Heslet L. Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH)-a review of a new treatment paradigm. Biologics 2012;6:37–46
   PubMedGoogle Scholar
• Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with hemophilia A and B, with and without inhibitor. Haemophilia 1998;4:790–798
   PubMed Web of Science ®Google Scholar
• Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Brit J Hematol 1997;99:542–547
   PubMed Web of Science ®Google Scholar
• Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Brit J Hematol 2001;114:114–120
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Zervas K, Arzoglou P, Karavaggeli E, Parashou S, Van Dreden P, Christakis J, Samama MM. On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: Focus on prothrombin activation. Brit J Hematol 2002;117:705–708
   PubMed Web of Science ®Google Scholar
• Parameswaran R, Shapiro AD, Gill GC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005;11:100–106
   PubMed Web of Science ®Google Scholar
• Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 2012;120:891–899
   PubMed Web of Science ®Google Scholar